NVO Stock Analysis: Buy, Sell, or Hold?
NVO - Novo-Nordisk A/S
$50.43
1.66 (3.40%)
▲
5d:
+5.86%
30d:
+17.5%
90d:
+38.24%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Distribution
None View Scanner →
Strength: 9.0/10
Get Alerted When NVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NVO is fairly valued with market pricing in 5.1% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: NVO is fairly valued with market pricing in 5.1% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$47.00
Based on 1.1% avg growth
INTRINSIC VALUE TODAY
$29.19
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVO is currently trading at $50.43, which is considered extended relative to its 30-day fair value range of $42.63 to $47.40. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.4) compared to its historical average (2.1). At these levels, the market is pricing in 5.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NVO is in a strong downtrend. The price is approaching resistance at $50.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: NVO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NVO is in a strong downtrend. The price is approaching resistance at $50.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: NVO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$42.63 -
$47.40
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
Protect Your Profits
NVO is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+6.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BEARISH: Trading above Wall St target ($47.62)
- NEUTRAL: Market pricing in 5.1% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$42.63 -
$47.40
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$42.52
Resistance Level
$50.90
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.38
Wall Street Target
$47.62
(-5.6%)
Revenue Growth (YoY)
24.0%
Earnings Growth (YoY)
67.1%
Profit Margin
37.2%
Valuation Premium vs History
+5.1% premium
PE vs Historical
2.4 vs 2.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.1%
(market-implied from PE analysis)
1-Year Target
$53.00
(+5%)
2-Year Target
$55.71
(+11%)
3-Year Target
$58.55
(+16%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
PE COMPRESSION
$51.72
(+3%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -1.8%)
$437.12
(+767%)
Base:
(SPY PE: 2.4, Growth: -1.8%)
$47.71
(-5%)
Bear:
(PE: 2.0, Growth: -1.8%)
$40.56
(-20%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 11.72 | Current EPS (TTM): $4.16
Bull Case
$107.29
(+113%)
Analyst growth 100.0%, PE expands to 12.9
Base Case
$97.54
(+93%)
Market implied 100.0%, PE stable at 11.7
Bear Case
$33.16
(-34%)
Severe decline -20.0%, PE contracts to 10.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 9:12 PM ET
Data refreshes hourly during market hours. Next update: 10:12 PM
Data refreshes hourly during market hours. Next update: 10:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 67 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 60 HOLD |
Advanced NVO Option Strategies
Professional options setups generated by AI based on today's NVO price and gamma walls.
